Pfizer’s sickle cell disease therapy Oxbryta recommended by NICE for NHS use
Pfizer’s Oxbryta (voxelotor) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat sickle cell disease (SCD) in patients aged 12 years and older. Affecting around 17,000 people in England, SCD is a life-long genetic …